UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 332

Sortiert nach

Zinc and Coronavirus Disease 2019

Clinical infectious diseases, 2023-08, Vol.77 (4), p.662-662

2023

Volltextzugriff (PDF)

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

The Lancet (British edition), 2017-11, Vol.390 (10107), p.2063-2072

2017

Volltextzugriff (PDF)

Generalizing evidence from randomized trials using inverse probability of sampling weights

Journal of the Royal Statistical Society. Series A, Statistics in society, 2018-10, Vol.181 (4), p.1193-1209

2018

Volltextzugriff (PDF)

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

The Journal of infectious diseases, 2011-06, Vol.203 (12), p.1791-1801

2011

Volltextzugriff (PDF)

Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults

PLoS genetics, 2021-04, Vol.17 (4), p.e1009464-e1009464

2021

Volltextzugriff (PDF)

Adherence to Antiretrovirals and HIV Viral Suppression Under COVID-19 Pandemic Interruption – Findings from a Randomized Clinical Trial Using Ingestible Sensors to Monitor Adherence

AIDS and behavior, 2023-12, Vol.27 (12), p.4041-4051

2023

Volltextzugriff (PDF)

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

Clinical infectious diseases, 2017-07, Vol.65 (1), p.6-12

2017

Volltextzugriff (PDF)

Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment

AIDS (London), 2011-03, Vol.25 (5), p.625-633

2011

Volltextzugriff (PDF)

Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men

Emerging infectious diseases, 2018-12, Vol.24 (12), p.2292-2302

2018

Volltextzugriff (PDF)

Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study

Clinical infectious diseases, 2018-05, Vol.66 (10), p.1566-1572

2018

Volltextzugriff (PDF)

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Nature communications, 2022-08, Vol.13 (1), p.4931-4931, Article 4931

2022

Volltextzugriff (PDF)

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data

Annals of internal medicine, 2014-07, Vol.161 (1), p.1

2014

Volltextzugriff (PDF)

Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results

The Journal of infectious diseases, 2011-10, Vol.204 (8), p.1191-1201

2011

Volltextzugriff (PDF)

Condomless Sex With Virologically Suppressed HIV-Infected Individuals: How Safe Is It?

JAMA : the journal of the American Medical Association, 2016-07, Vol.316 (2), p.149

2016

Volltextzugriff (PDF)

Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV

Journal of acquired immune deficiency syndromes (1999), 2019-01, Vol.80 (1), p.e9

2019

Volltextzugriff (PDF)

Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2016-07, Vol.316 (2), p.156

2016

Volltextzugriff (PDF)

Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens

Clinical infectious diseases, 2021-10, Vol.73 (7), p.e2153-e2163

2021

Volltextzugriff (PDF)

Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314

Clinical infectious diseases, 2019-05, Vol.68 (11), p.1877-1886

2019

Volltextzugriff (PDF)

Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men

The Journal of infectious diseases, 2018-10, Vol.218 (10), p.1551-1559

2018

Volltextzugriff (PDF)

Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody

PLoS pathogens, 2024-04, Vol.20 (4), p.e1011680

2024

Volltextzugriff (PDF)

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1

Annals of internal medicine, 2011-04, Vol.154 (7), p.445

2011

Volltextzugriff (PDF)

Next generation fixed dose combination pharmacotherapies for treating HIV

Expert opinion on pharmacotherapy, 2018-04, Vol.19 (6), p.589-596

2018

Volltextzugriff (PDF)

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I

AIDS (London), 2022-09, Vol.36 (11), p.1511-1520

2022

Volltextzugriff (PDF)

Alterations of gray and white matter volumes and cortical thickness in treated HIV-positive patients

Magnetic resonance imaging, 2023-01, Vol.95, p.27-38

2023

Volltextzugriff (PDF)

1 – 25 von 332

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(316)
Mit Volltextzugriff
(263)

Publikationsform

Sprache

Englisch
(332)
Japanisch
(23)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Zinc and Coronavirus Disease 2019

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Generalizing evidence from randomized trials using inverse probability of sampling weights

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults

Adherence to Antiretrovirals and HIV Viral Suppression Under COVID-19 Pandemic Interruption – Findings from a Randomized Clinical Trial Using Ingestible Sensors to Monitor Adherence

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment

Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men

Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data

Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results

Condomless Sex With Virologically Suppressed HIV-Infected Individuals: How Safe Is It?

Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV

Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial

Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens

Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314

Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men

Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1

Next generation fixed dose combination pharmacotherapies for treating HIV

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I

Alterations of gray and white matter volumes and cortical thickness in treated HIV-positive patients

Suchergebnisse filtern